Market Outlook: NSCLC has one of the most dynamic drug development pipelines in oncology with multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience…
Myelofibrosis is a hematological malignancy characterized by the disrupted production of blood cells and bone marrow scarring; symptoms include severe anemia, weakness, fatigue, and splenomegaly…
The type 2 diabetes therapy market will steadily expand over our 2017-2027 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in…
Market Outlook The migraine prophylaxis market stands poised for disruption following the launch of three anti-CGRP monoclonal antibodies (MAbs) in the United States in 2018, with a fourth to…
Although angiogenesis inhibitors are a mainstay in the treatment of renal cell carcinoma, Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibitor, Opdivo, has captured significant market share…
Market Outlook The migraine prophylaxis market stands poised for disruption following the launch of three anti-CGRP monoclonal antibodies (MAbs) in the United States in 2018, with a fourth to…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Market Outlook Immune checkpoint inhibitors are revolutionizing the treatment algorithm for unresectable locally advanced or metastatic bladder cancer. Following the 2016/7 FDA approvals of five…
Market Outlook Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the main treatment for prostate cancer and are routinely used throughout the course…
Because no current therapy for type 2 diabetes offers disease-modifying capabilities, a high unmet need exists for drugs that can effectively control the progression of this prevalent disease…
Market Outlook: Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, with the majority of cases arising from underlying liver cirrhosis. Treatment of HCC incorporates a variety of…
DRG Epidemiology's coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations across the emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia…
DRG Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations in the Asia pacific pharmaceutical markets (Australia, Hong Kong, Indonesia,…
MARKET OUTLOOK The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population,…
The treatment journey for multiple sclerosis (MS) patients in Europe is complicated and individualized, driven by the availability of a broad array of disease-modifying therapies (DMTs)—…